Manufacturers: Antag Therapeutics
AT-7687 is a first-in-class GIP receptor antagonist peptide developed by Antag Therapeutics for the treatment of obesity, cardiometabolic disease, and related metabolic conditions. Phase 1 results demonstrated favorable tolerability and suitability for once-weekly subcutaneous dosing. A Phase 2a study is expected to commence in mid-2026.
AT-7687 is a first-in-class GIP receptor antagonist peptide developed by Antag Therapeutics for the treatment of obesity, cardiometabolic disease, and related metabolic conditions. Phase 1 results demonstrated favorable tolerability and suitability for once-weekly subcutaneous dosing. A Phase 2a study is expected to commence in mid-2026.
AT-7687 is a first-in-class glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist peptide. It is specifically designed to target and deactivate the GIP receptor, a genetically validated pathway implicated in fat storage, insulin resistance, and metabolic dysfunction. Based on decades of research by GLP-1 pioneer Professor Jens Juul Holst.
Obesity; cardiometabolic disease; type 2 diabetes; overweight (investigational)
4 associated conditions
